Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 29;24(11):9429.
doi: 10.3390/ijms24119429.

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer

Jacobi B Hines  1 , Benjamin Bowar  1 , Emma Levine  2 , Alessandra Esposito  1 , Marina C Garassino  1 , Christine M Bestvina  1
Affiliations
Review

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer

Jacobi B Hines et al. Int J Mol Sci. .

Abstract

Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment.

Keywords: adverse drug events; molecular targeted therapies; non-small cell lung cancer; pharmacovigilance; toxicity.

PubMed Disclaimer

Conflict of interest statement

B.C.M. reports institutional research funding from AstraZeneca and Bristol-Myers Squibb; advisory board membership/consulting for AstraZeneca, Bristol-Myers Squibb, CVS, Genentech, Janssen Biotech, Jazz, JNJ, Novartis, Pfizer, Regeneron, Sanofi, Seattle Genetics, and Takeda; and membership in a speakers’ bureau for Merck. The other authors declare that there is no conflict of interest.

References

    1. Majeed U., Manochakian R., Zhao Y., Lou Y. Targeted therapy in advanced non-small cell lung cancer: Current advances and future trends. J. Hematol. Oncol. 2021;14:108. doi: 10.1186/s13045-021-01121-2. - DOI - PMC - PubMed
    1. Dang A.H., Tran V.U., Tran T.T., Thi Pham H.A., Le D.T., Nguyen L., Nguyen N.V., Thi Nguyen T.H., Nguyen C.V., Le H.T., et al. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci. Rep. 2020;10:2707. doi: 10.1038/s41598-020-59744-3. - DOI - PMC - PubMed
    1. Gebbia V., Bellavia M., Banna G.L., Russo P., Ferrau F., Tralongo P., Borsellino N. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clin. Lung Cancer. 2013;14:390–398. doi: 10.1016/j.cllc.2012.11.007. - DOI - PubMed
    1. Neuss M.N., Gilmore T.R., Belderson K.M., Billett A.L., Conti-Kalchik T., Harvey B.E., Hendricks C., LeFebvre K.B., Mangu P.B., McNiff K., et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. J. Oncol. Pract. 2016;12:1262–1271. doi: 10.1200/JOP.2016.017905. - DOI - PubMed
    1. Finn A., Bondarenka C., Edwards K., Hartwell R., Letton C., Perez A. Evaluation of electronic health record implementation on pharmacist interventions related to oral chemotherapy management. J. Oncol. Pharm. Pract. 2017;23:563–574. doi: 10.1177/1078155216665247. - DOI - PubMed

MeSH terms

Substances